Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions
DRUG

GTX-104

Nimodipine IV infusion

DRUG

Nimotop 30 MG Oral Capsule

Oral nimodipine capsules

Trial Locations (22)

10029

The Mount Sinai Hospital, New York

21201

University of Maryland Medical Center, Baltimore

23298

Virginia Commonwealth University, Richmond

27599

University of North Carolina, Chapel Hill

27710

Duke University, Durham

30303

Emory University School of Medicine Emergency Neurosciences, Atlanta

32224

Mayo Clinic Florida, Jacksonville

35233

The University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

38104

Methodist University Hospital, Memphis

40536

University of Kentucky Hospital, Lexington

43210

The Ohio State University Wexner Medical Center, Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

45219

University of Cincinnati Medical Center, Cincinnati

46202

Indiana University Health Methodist Hospital, Indianapolis

60611

Northwestern Feinberg Pavillion Neuro and Spine ICU, Chicago

63110

Washington University, St Louis

77030

University of Texas Health Science Center at Houston, Houston

85013

Brain and Spine Neurological Institute, Phoenix

93701

Community Regional Medical Center, Fresno

97239

Oregon Health and Science University, Portland

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Grace Therapeutics Inc.

INDUSTRY

NCT05995405 - Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH | Biotech Hunter | Biotech Hunter